Wells Fargo’s Apexigen, Inc. Common Stock APGN Stock Holding History

Wells Fargo’s Portfolio APGN Stock Details APGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-154	Closed	-$66	–	7753
2023 Q2	$66	Buy	154 +6	+4%	+$3	﹤0.01%	6983
2023 Q1	$72	Buy	148 +21	+17%	+$25	﹤0.01%	7018
2022 Q4	$87	Buy	127 +3	+2%	+$6	﹤0.01%	6832
2022 Q3	$0	Buy	+124	New	+$1.01K	﹤0.01%	7707

Wells Fargo's APGN Position: Q3 2023 in Review

Wells Fargo sold out of Apexigen, Inc. Common Stock (APGN) in Q3 2023, closing a stake of 154 shares — an estimated $66 sold.

Wells Fargo first reported a position in APGN in Q3 2022 and held it in 4 quarters. The position peaked at $87 in Q4 2022. 0 funds tracked by Wall St. Rank hold APGN as of Q3 2023.

Wells Fargo reported no remaining Apexigen, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Wells Fargo sold 154 Apexigen, Inc. Common Stock shares in Q3 2023, an estimated $66.
Wells Fargo first reported a position in Apexigen, Inc. Common Stock in Q3 2022 and held it in 4 quarters.
Wells Fargo's Apexigen, Inc. Common Stock position peaked at $87 in Q4 2022.
0 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q3 2023.

Based on Wells Fargo's 13F filing for Q3 2023, filed 13 Nov 2023.